Zhejiang Huakang Pharmaceutical Co Ltd (605077) - Net Assets
Based on the latest financial reports, Zhejiang Huakang Pharmaceutical Co Ltd (605077) has net assets worth CN¥3.24 Billion CNY (≈ $474.60 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.56 Billion ≈ $1.11 Billion USD) and total liabilities (CN¥4.32 Billion ≈ $632.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Zhejiang Huakang Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.24 Billion |
| % of Total Assets | 42.87% |
| Annual Growth Rate | 48.71% |
| 5-Year Change | 246.49% |
| 10-Year Change | N/A |
| Growth Volatility | 54.56 |
Zhejiang Huakang Pharmaceutical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Zhejiang Huakang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check 605077 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Zhejiang Huakang Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual net assets of Zhejiang Huakang Pharmaceutical Co Ltd from 2016 to 2024. For live valuation and market cap data, see 605077 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.26 Billion ≈ $476.36 Million |
+4.98% |
| 2023-12-31 | CN¥3.10 Billion ≈ $453.78 Million |
+16.76% |
| 2022-12-31 | CN¥2.66 Billion ≈ $388.63 Million |
+9.09% |
| 2021-12-31 | CN¥2.43 Billion ≈ $356.23 Million |
+159.11% |
| 2020-12-31 | CN¥939.52 Million ≈ $137.48 Million |
+37.20% |
| 2019-12-31 | CN¥684.81 Million ≈ $100.21 Million |
+55.31% |
| 2018-12-31 | CN¥440.92 Million ≈ $64.52 Million |
+134.54% |
| 2017-12-31 | CN¥187.99 Million ≈ $27.51 Million |
+38.14% |
| 2016-12-31 | CN¥136.09 Million ≈ $19.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Huakang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 122589901046.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.20 Billion | 37.02% |
| Other Components | CN¥2.04 Billion | 62.98% |
| Total Equity | CN¥3.24 Billion | 100.00% |
Zhejiang Huakang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Huakang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sebang Global Battery Co Ltd
KO:004490
|
$474.08 Million |
|
AB Sagax (publ)
ST:SAGA-A
|
$474.09 Million |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
$474.10 Million |
|
Jiangsu Lianfa Textile Co Ltd
SHE:002394
|
$474.15 Million |
|
Bouvet
OL:BOUV
|
$473.95 Million |
|
MN Holdings Berhad
KLSE:0245
|
$473.81 Million |
|
Coca-Cola Embonor S.A
SN:EMBONOR-B
|
$473.76 Million |
|
Stenhus Fastigheter I Norden AB
ST:SFAST
|
$473.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Huakang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,089,432,600 to 3,243,431,005, a change of 153,998,406 (5.0%).
- Net income of 268,483,887 contributed positively to equity growth.
- Dividend payments of 196,557,745 reduced retained earnings.
- Other factors increased equity by 82,072,264.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥268.48 Million | +8.28% |
| Dividends Paid | CN¥196.56 Million | -6.06% |
| Other Changes | CN¥82.07 Million | +2.53% |
| Total Change | CN¥- | 4.98% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Huakang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.32x to 1.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.28 | CN¥10.69 | x |
| 2017-12-31 | CN¥1.80 | CN¥10.69 | x |
| 2018-12-31 | CN¥3.74 | CN¥10.69 | x |
| 2019-12-31 | CN¥4.00 | CN¥10.69 | x |
| 2020-12-31 | CN¥7.67 | CN¥10.69 | x |
| 2021-12-31 | CN¥11.00 | CN¥10.69 | x |
| 2022-12-31 | CN¥11.65 | CN¥10.69 | x |
| 2023-12-31 | CN¥10.13 | CN¥10.69 | x |
| 2024-12-31 | CN¥10.60 | CN¥10.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Huakang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.28%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.56%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.16x
- Recent ROE (8.28%) is below the historical average (23.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 21.13% | 3.76% | 1.12x | 5.02x | CN¥15.12 Million |
| 2017 | 29.79% | 6.05% | 1.32x | 3.74x | CN¥37.16 Million |
| 2018 | 45.22% | 14.24% | 1.34x | 2.38x | CN¥155.29 Million |
| 2019 | 39.44% | 17.88% | 1.31x | 1.69x | CN¥201.63 Million |
| 2020 | 32.69% | 23.28% | 0.92x | 1.52x | CN¥213.22 Million |
| 2021 | 9.72% | 14.85% | 0.53x | 1.23x | CN¥-6.74 Million |
| 2022 | 12.02% | 14.51% | 0.56x | 1.47x | CN¥53.70 Million |
| 2023 | 12.02% | 13.35% | 0.45x | 2.00x | CN¥62.51 Million |
| 2024 | 8.28% | 9.56% | 0.40x | 2.16x | CN¥-55.86 Million |
Industry Comparison
This section compares Zhejiang Huakang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $1,949,788,034
- Average return on equity (ROE) among peers: -27.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Huakang Pharmaceutical Co Ltd (605077) | CN¥3.24 Billion | 21.13% | 1.33x | $474.06 Million |
| North Huajin Chemical Industries Co Ltd (000059) | $7.39 Billion | 0.27% | 3.43x | $964.28 Million |
| Sichuan Chemical Co Ltd (000155) | $553.00 Million | 18.19% | 1.35x | $3.19 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $1.42 Billion | 5.76% | 1.19x | $12.03 Billion |
| Zangge Holding Co Ltd (000408) | $177.18 Million | 2.60% | 1.55x | $16.78 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $511.27 Million | 0.41% | 0.86x | $1.87 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $38.72 Million | -326.47% | 8.38x | $382.67 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $2.81 Billion | 10.94% | 2.26x | $823.93 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $2.77 Billion | 1.89% | 0.12x | $355.27 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $824.49 Million | 10.82% | 0.01x | $268.54 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $3.01 Billion | 3.69% | 0.89x | $3.05 Billion |
About Zhejiang Huakang Pharmaceutical Co Ltd
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltito… Read more